Image

We’re Aware— Now What?

A Patient’s Perspective on the Need for Research

by Ann Silberman

Part 1 of 6: We’re Aware— Now What?
SHARE  
 
Social Icon

To every thing there is a season, and a time to every purpose under Heaven,” goes the lyric in the song Turn, Turn, Turn, written by Pete Seeger in the 1950s. For those of us with metastatic breast cancer, that lyric takes on a deeper meaning. Not only do we live with the knowledge that our time is short and our season is waning, but we also exist within a culture that aims a pink spotlight at the wrong cause: breast cancer awareness.

Awareness, as defined by breast cancer organizations, means understanding that breast cancer exists and taking steps to get it diagnosed as early as possible. If you do those things, they contend, you will survive. But once cancer becomes incurable, many of us realize that the focus on awareness is out of sync with the reality of the problem: a need for more research.

Over the past 30 years, billions of dollars have been spent on this concept of awareness. Despite these well-meaning campaigns, statistics show that the number of deaths from breast cancer has hovered above the 40,000 range for the past two decades. And there are still many gaps in our scientific knowledge of the disease itself.

At this point, everybody—from the second-grader down the street to your centurion great-grandfather—knows what breast cancer is, and that mammographic screening is the detection tool of choice. But this wasn’t always so. Back in the mid-1970s, the culture wasn’t as open. Just a few years earlier, Rob and Laura Petrie on the Dick Van Dyke Show had to sleep in twin beds so as not to offend the public’s sensibilities. Breast cancer simply wasn’t talked about. Muscle and sometimes bone were removed along with breast tissue in mastectomies, which was extremely disfiguring, and women only admitted to undergoing them in hushed whispers.

Billions of dollars have been spent on awareness, but about 40,000 women have been dying from breast cancer every year since the ’90s.

First Lady Betty Ford was diagnosed with breast cancer, and in 1974, she publicly announced that she’d had a mastectomy. Ford was applauded for being open about the disease because many women felt that they could finally confess that they too had undergone mastectomies. There was even a jump in the number of breast cancer diagnoses after the announcement. Women with lumps cast off their embarrassment and flooded doctors offices to get them checked out.

When the main breast cancer charities came along in the mid-1980s, society had begun to change. Women had burned their bras in the name of equal rights, and sexuality— including breasts—were becoming advertising vehicles. The time was right to bring breast cancer into the public spotlight.

Image
section 2

The Phenomenon of Cause Marketing

Why Products Are Plastered with Pink Ribbons Every October

National Breast Cancer Awareness Month (NBCAM) was started by a pharmaceutical company that had ties to tamoxifen, an anti-cancer drug still used widely today. The aim of NBCAM was to make sure every woman was aware of this disease, and to promote mammography as the most powerful weapon in the fight against breast cancer. Back in the 1980s, this seemed like a reasonable goal. Is it still today?

Finding cancer early enough to prevent spread would be a worthy goal if that was all there was to curing cancer, but it’s not.

Every October, companies plaster products from soup to vacuum cleaners with pink banners and those ubiquitous pink ribbons under the guise of helping cancer patients. Termed “cause marketing,” a percentage of the profits from these products are promised to breast cancer awareness charities, garnering companies the tax break they desire while advertising the good they want us to believe they are doing. Even small businesses, such as bars and restaurants, get in on the hype, promoting pink drinks and donating a portion of the profits. The White House, the Empire State Building, and the uniforms of NFL athletes all turn pink—all for the cause of breast cancer awareness.

The Susan G. Komen Foundation is the charity perhaps most closely associated with breast cancer. Despite having had “for the cure” in its name for most of its existence, this organization focuses on awareness rather than research. And many charities follow suit, raking in tens of millions of dollars yearly. But is spending money on all this awareness still necessary? Breasts are now out and proud—there’s no longer embarrassment associated with having them or having them removed.

Having worked as a school employee from elementary to high school, I know firsthand that children at every grade level are aware of breast cancer. “I heart boobies” bracelets are popular, especially among the middle school set. When you ask children why they’re wearing them, the universal answer is “To support breast cancer.” (The real answer is because the message is subversively trendy.)

Even third to fifth graders can converse on the topic. Many have had teachers or parents with breast cancer, and they too live in a culture that turns pink every October. I’ve seen small kids collect pennies for breast cancer awareness and wear pink at Little League games, saying the word “breast” as casually as they would any other body part.

For many women, their first mammogram is as much a rite of passage as is their first period, and women often talk about at what age they got their “baseline.” In 2014, women aren’t afraid to go see doctors for screenings. And now, cancer is the first thing they think of upon finding a lump, not the last.

If the goal of breast cancer awareness has been achieved—and I believe it has—then that still leaves early detection. Finding cancer early enough to prevent spread would be a worthy goal if that was all there was to curing cancer. Unfortunately, there’s no evidence to suggest that it is, and there’s plenty to prove that it isn’t.

Image
section 3

The False Safety of Early Detection

What the Unpredictability of Metastasis Means

Ninety to 96 percent of women who now have metastatic breast cancer were diagnosed at an early stage.

According to the Metastatic Breast Cancer Network (MBCN), 90 to 96 percent of women who now have metastatic disease were diagnosed at an early stage. This is an important fact. It means that almost every single woman who has terminal breast cancer today can sit under the “early detection” umbrella. Most went through treatment and then discovered that their cancer had unexpectedly spread. I’m one of them.

In 2009, I was diagnosed with stage 2a breast cancer with no infected nodes and no indication that my cancer had metastasized. I had a mastectomy, six rounds of chemo, and a year of Herceptin. I was believed to be on my way to a long, healthy life—until 2011, when breast cancer was found in my liver. My disease is now incurable. Contrast that to some of my friends who were diagnosed at the same time as I was. Several were stage 3c with a dire prognosis, yet they’re healthy today, and cancer-free. I was the only one who progressed to stage 4. While personal examples are merely anecdotal evidence, statistics echo this phenomenon.

People are logical. We like order. But unfortunately, cancer doesn’t neatly progress from stage 1 to 2, 2 to 3, and 3 to 4. Some cancer cells take an immediate ride through the body, hiding in an organ until something sparks growth two, five—even 10 years later. Other cancers won’t, rendering early detection meaningless for many. Only research can tell when, why, or in whom metastases will happen. That is data we currently don’t have.

Image
section 4

The Dangers of Overscreening

More Mammograms Aren’t Necessarily a Good Thing

A 25-year analysis found that screening didn’t decrease the risk of dying from cancer. And regular screening itself carries risks.

We’ve learned much about breast cancer since the 1980s, and the idea of yearly mammography for regular screening is so deep-seated in our culture that women become enraged at the suggestion that we may be over-screening. Yet, it’s true. Study after study has highlighted the limits of breast cancer screening. The latest study, which was published in the British Medical Journal, was a 25-year analysis that concluded screening didn’t decrease the risk of dying from cancer. Still, many women have been indoctrinated for decades with the message that they must have yearly mammograms, and nothing will talk them out of it.

While nobody is suggesting that women never should get mammograms, it’s becoming increasingly clear that regular screening itself carries risks. The National Cancer Institute reports that fewer than five of 1,000 women actually have breast cancer when they’re screened. That means most abnormal mammograms are false positives, which cause a tremendous amount of anxiety and unnecessary biopsies. And mammograms are now finding a precancerous condition called ductal carcinoma in situ (DCIS), or “stage 0” cancer. DCIS is not a true cancer. It’s not invasive and can’t kill, but it must be treated like cancer because in some cases, it does become invasive. There are only subtle clues that hint at which DCIS may end up becoming dangerous, and thus no form of it can be ignored.

The American Cancer Society reports that the incidence of DCIS increased seven-fold from 1980. Many doctors believe that up to half of these DCIS cases would have disappeared in time. And up to 14 percent of women who died from other causes had DCIS according to their autopsies, and never knew it. Awareness and overscreening has led to hundreds of thousands of disfiguring surgeries for something that never may have hurt them—if only we knew more about it.

Image
section 5

The Well-Funded Awareness Machine

The Majority of Donation Dollars Don’t Go to Finding a Cure

Finding cancer early doesn’t always save one from metastases. So it seems logical that at least a larger portion of charitable dollars should be spent on helping those with end-stage breast cancer. But independent research dollars are difficult to come by.

The Susan G. Komen Foundation donates only 17 percent of their millions to research. Most goes towards races, literature, and ads.

The Susan G. Komen Foundation (also known as Komen), by far the largest breast cancer charity, only donates 17 percent of their millions to fund research grants. And MBCN estimates that less than five percent of all charitable money goes towards research for metastases, the only form of breast cancer that kills. The rest of the money is funneled back into awareness and education. Races are sponsored, literature is distributed, breast self-exams are advertised, and of course, mammogram machines for clinics are funded. But little is spent to help save those who are dying in the last stages of the disease.

Komen is not alone. Even smaller charities, such as the Keep a Breast Foundation, don’t fund breast cancer research. Their money goes towards making plastic awareness bracelets and giving their executives large salaries, while sending the rest into “green” foundations and other initiatives that have nothing to do with the disease. Cancer funding is often left to drug companies or the government.

Image
section 6

A Call to Action

Shifting the Focus from Raising

Awareness to Saving Lives

To become aware, one must understand two important facts: that the only people who die of breast cancer are the people whose cancer has spread outside the breast (when it’s contained in the breast, it can’t kill), and that one is not necessarily safe after treatment—even after a mastectomy to remove the cancer. The risk for relapse, according to the American Cancer Society, is one in five. Today, as was the case 20 years ago, every woman with metastatic disease will die. That’s 40,000 women every year.

Awareness should no longer be the main breast cancer agenda in 2014. It’s time to roll up the pink ribbons and focus on research.

Treatment options for metastatic largely remain the same as they have always been: radiation and chemo. Women with HER2+ cancer, an aggressive form of the disease, are fortunate enough to have Herceptin, Perjeta, and Kadcyla in their arsenal, new drugs that have extended lives by months, including mine. But for women with triple negative breast cancer (TNBC), another aggressive cancer, there’s still no magic drug. And unlike with other cancers, a metastatic spread of breast cancer—typically to the brain, lung, liver, or bones—is always fatal. Awareness hasn’t changed the most important numbers.

The breast cancer agenda shouldn’t be finding breast cancer. It should be saving those afflicted with the disease: figuring out which DCIS becomes invasive, and learning about the system of metastases. Just think, if all the dollars that awareness charities raised during the month of October went to labs and competent research doctors instead of marketing experts, the problem of breast cancer—and other cancers along with it—might be solved.

Breast cancer awareness and early detection in 2014 are as relevant as PalmPilots or twin beds for married couples. The true race for a cure has yet to begin. It’s time to put down the pink flags, roll up the ribbons, and focus on change.

As Pete Seeger said, it’s time to “turn, turn, turn.” We must turn away from awareness and towards research.

Image

About the Writer

Ann Silberman is a writer whose personal blog “ But Doctor...I Hate Pink ” has reached nearly two million views. She was diagnosed with early-stage breast cancer in 2009. In 2011, the cancer metastasized to her liver. Her goal was to live long enough to see her youngest son graduate high school in June of 2014. She is happily working on finding a new goal.

Learn More About Ann

References:

• Breast cancer facts and figures 2011-2012. (n.d.). American Cancer Society. Retrieved February 26, 2014, from

http://www.cancer.org/acs/groups/ content/@epidemiologysurveilance/ documents/document/acspc-030975.pdf

• 13 facts everyone should know about metastatic breast cancer. (n.d.). Metastatic Breast Cancer Network. Retrieved February 27, 2014, from

http://mbcn.org/developing-awareness/category/13-things-everyone-should-know-about-metastatic-breast-cancer

• Most common statistics cited for MBC (n.d.). Metastatic Breast Cancer Network. Retrieved February 27, 2014, from

http://mbcn.org/education/category/most-commonly-used-statistics-for-mbc

• Deaths and mortality rates. (n.d.). Metastatic Breast Cancer Network. Retrieved February 27, 2014 from

http://mbcn.org/education/category/deaths-and-mortality-rates

• Welch, HG, Black, WC. (1997, December 1). Using autopsy series to estimate the disease “reservoir” for ductal carcinoma in situ of the breast: how much breast cancer can we find? Annals of Internal Medicine, 127 (11): 1023-1028. Retrieved February 27, 2014, from

http://www.ncbi.nlm.nih.gov/pubmed/9412284

• Miller, A. B., Wall, C., Baines, C., Sun, P., Tu, T., & Narod, S. (2014, February 11). Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. British Medical Journal. Retrieved February 26, 2014, from

http://www.bmj.com/content/348/bmj.g366

• Mayer, M., Hunis, A., Oratz, R., Glennon, C., Spicer, P., Caplan, E., Fallowfield, L. (2010, September). Living with metastatic breast cancer: a global patient survey. Oncology Practice, 7 (9): 406-412. Retrieved February 25, 2014, from

http://www.oncologypractice.com/co/journal/articles/ 0709406.pdf

• Sleeman, J., Steeg, P. (2010, May 15). Only five percent of cancer research funds are spent on metastases, yet it kills 90 percent of all cancer patients. American Cancer Organisation. Retrieved February 27, 2014, from

http://www.alphagalileo.es/Organisations/ ViewItem.aspx?OrganisationId=801&ItemId=77342&CultureCode=en

• Research. (n.d.). METAvivor Breast Cancer and Support. Retrieved February 27, 2014, from

http://www.metavivor.org/research/

• Sleeman, J., & Steeg, P. S. (2010). Cancer metastasis as a therapeutic target. European Journal of Cancer, 46 (7), 1177-1180. retreived, Feb 26, 2014 from

http://www.ejcancer.com/article/S0959-8049(10)00166-8/abstract

• Study quantifies risk of breast cancer recurrence. (2008, September 17). American Cancer Society. Retrieved February 27, 2014, from

http://www.cancer.org/cancer/news/news/study-quantifies-risk-of-breast-cancer-recurrence

• Harms of screening mammography. (2014, February 21). National Cancer Institute. Retrieved March 6, 2014 from

http://www.cancer.gov/cancertopics/pdq/screening/ breast/healthprofessional/page8

• Breast cancer statistics. (2013, October 23). Centers for Disease Control and Prevention. Retrieved from http://www.cdc.gov/cancer/breast/statistics/?mobile=nocontent.

• Deaths from breast cancer—United States, 1991. (1994, April 22). Centers for Disease Control and Prevention. Retrieved from http://www.cdc.gov/mmwr/preview/mmwrhtml/00026281.htm?mobile=nocontent.

Image

Copyright © 2005 - 2014 Healthline Networks, Inc. All rights reserved. Healthline is for informational purposes and should not be considered medical advice, diagnosis or treatment recommendations.

Terms of Use  |  Privacy Policy